GERN
Price
$1.35
Change
-$0.02 (-1.46%)
Updated
Sep 11 closing price
Capitalization
864.13M
60 days until earnings call
Intraday BUY SELL Signals
VIR
Price
$10.62
Change
+$0.04 (+0.38%)
Updated
Sep 11 closing price
Capitalization
1.8B
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GERN vs VIR

GERN vs VIR Comparison Chart in %
View a ticker or compare two or three
VS
GERN vs. VIR commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a Hold and VIR is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VIR($1.8B) has a higher market cap than GERN($864M). VIR YTD gains are higher at: 76.119 vs. GERN (2.273). GERN has higher annual earnings (EBITDA): -36.13M vs. VIR (-268.68M). VIR has more cash in the bank: 533M vs. GERN (301M). VIR has less debt than GERN: VIR (93.3M) vs GERN (122M). VIR has higher revenues than GERN: VIR (303M) vs GERN (205M).
GERNVIRGERN / VIR
Capitalization864M1.8B48%
EBITDA-36.13M-268.68M13%
Gain YTD2.27376.1193%
P/E RatioN/AN/A-
Revenue205M303M68%
Total Cash301M533M56%
Total Debt122M93.3M131%
FUNDAMENTALS RATINGS
GERN vs VIR: Fundamental Ratings
GERN
VIR
OUTLOOK RATING
1..100
6388
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
96100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
5937
P/E GROWTH RATING
1..100
6423
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VIR's Valuation (57) in the null industry is somewhat better than the same rating for GERN (100) in the Biotechnology industry. This means that VIR’s stock grew somewhat faster than GERN’s over the last 12 months.

GERN's Profit vs Risk Rating (96) in the Biotechnology industry is in the same range as VIR (100) in the null industry. This means that GERN’s stock grew similarly to VIR’s over the last 12 months.

GERN's SMR Rating (96) in the Biotechnology industry is in the same range as VIR (96) in the null industry. This means that GERN’s stock grew similarly to VIR’s over the last 12 months.

VIR's Price Growth Rating (37) in the null industry is in the same range as GERN (59) in the Biotechnology industry. This means that VIR’s stock grew similarly to GERN’s over the last 12 months.

VIR's P/E Growth Rating (23) in the null industry is somewhat better than the same rating for GERN (64) in the Biotechnology industry. This means that VIR’s stock grew somewhat faster than GERN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GERNVIR
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 12 days ago
73%
Declines
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
71%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (GERN: $1.35 vs. VIR: $10.62)
Brand notoriety: GERN and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GERN: 51% vs. VIR: 96%
Market capitalization -- GERN: $864.13M vs. VIR: $1.8B
GERN [@Biotechnology] is valued at $864.13M. VIR’s [@Biotechnology] market capitalization is $1.8B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GERN’s FA Score shows that 0 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).

  • GERN’s FA Score: 0 green, 5 red.
  • VIR’s FA Score: 1 green, 4 red.
According to our system of comparison, VIR is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GERN’s TA Score shows that 3 TA indicator(s) are bullish while VIR’s TA Score has 5 bullish TA indicator(s).

  • GERN’s TA Score: 3 bullish, 4 bearish.
  • VIR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, VIR is a better buy in the short-term than GERN.

Price Growth

GERN (@Biotechnology) experienced а -14.01% price change this week, while VIR (@Biotechnology) price change was -6.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

GERN is expected to report earnings on Nov 11, 2026.

VIR is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
GERN
Daily Signal:
Gain/Loss:
VIR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FQAL83.670.63
+0.76%
Fidelity Quality Factor ETF
THY21.45N/A
N/A
Toews Agility Dynamic Tactical Inc ETF
NCIQ15.90N/A
N/A
Hashdex Nasdaq CME Crypto Index ETF
VMSB48.58-0.38
-0.78%
Voya Multi Sector Income ETF
HIBS18.61-1.35
-6.76%
Direxion Daily S&P 500® Hi Bt Br 3X ETF

VIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIR
1D Price
Change %
VIR100%
+0.38%
BEAM - VIR
54%
Loosely correlated
-1.56%
DNLI - VIR
52%
Loosely correlated
-1.45%
EDIT - VIR
51%
Loosely correlated
+1.89%
RCUS - VIR
50%
Loosely correlated
-5.97%
CRBU - VIR
49%
Loosely correlated
-7.30%
More